Aclarion, Inc. (ACON) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Aclarion, Inc. is a healthcare technology company leveraging magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The company is classified as an emerging growth company and a smaller reporting company. As of August 14, 2024, there were 8,610,671 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | Q2 2023 (3 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Revenue | $10,971 | $21,085 | $17,072 | $42,542 |
| Net Loss | $(1,238,077) | $(3,637,180) | $(1,464,557) | $(2,648,017) |
| Diluted EPS | $(0.15) | $(0.53) | $(2.83) | $(5.22) |
| Cash & Equivalents | $1,172,687 (as of June 30, 2024) | |||
| Total Debt (Note Payable) | $777,087 (net of discount, as of June 30, 2024) | |||
| Stockholders' Equity | $1,642,177 (as of June 30, 2024) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 36% quarter-over-quarter (Q2 2024 vs. Q2 2023) and 50% year-to-date, primarily due to the conclusion of clinical activity at customer sites utilizing NOCISCAN reports.
- Operating Expenses: Total operating expenses decreased 20% QoQ and 8% YTD. General and Administrative (G&A) expenses dropped significantly (26% QoQ) due to reduced bonus accruals, lower D&O insurance premiums, and lower legal fees compared to the prior year.
- Debt Restructuring: The company executed significant debt-for-equity exchanges in early 2024. In January 2024, $1.52 million in debt was exchanged for common stock, resulting in a $1.07 million loss on exchange of debt. In March 2024, a partial cash repayment resulted in a $111,928 loss on extinguishment of debt.
- Capital Raising: In February 2024, the company completed a public offering raising approximately $3.0 million gross. Additionally, proceeds of approximately $1.75 million were raised via an equity line of credit during the six-month period.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: Management states that current cash resources are sufficient to fund operations into the third quarter of 2024, approaching the maturity of an unsecured non-convertible note due in September 2024. The filing explicitly states that recurring losses and the need for additional financing raise substantial doubt as to the Company's ability to continue as a going concern.
- Nasdaq Compliance: The company received a notice from Nasdaq on April 8, 2024, regarding non-compliance with the $1.00 minimum bid price requirement. The company has 180 days (until October 7, 2024) to regain compliance, potentially via a reverse stock split.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2024, citing material weaknesses related to limited segregation of duties and a lack of adequate accounting resources for complex transactions.
- Subsequent Events: On August 14, 2024, the company entered into an exchange agreement to convert the remaining $930,052 of principal and accrued interest on its notes into Series B convertible preferred stock, eliminating the remaining balance of these notes.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to secure funding before the September 2024 note maturity, given the "substantial doubt" going concern warning.
- Nasdaq Status: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement by October 7, 2024, to avoid delisting.
- Revenue Sustainability: Assess the pipeline for new clinical contracts to replace the revenue lost from concluded customer site activities.
- Debt Resolution: Confirm the final terms and dilution impact of the August 2024 exchange of remaining debt for Series B convertible preferred stock.
- Internal Controls: Review progress on remediation efforts for material weaknesses in internal controls over financial reporting.